Derkach Nemirovsky

10PUBLICATIONS
55CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve

|Mar 30, 2026
Correction: Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease.

Gagan Raju, Moneeza Walji, David Nemirovsky

|Nov 02, 2025
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma.

Eric Jurgens, Tala Shekarkhand, Colin Rueda

|Oct 13, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana

|Oct 04, 2025
Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease.

Gagan Raju, Moneeza Walji, David Nemirovsky

|Sep 27, 2025
Venetoclax in Combination With Pediatric-Inspired Chemotherapy in Adults With Newly Diagnosed Acute Lymphoblastic Leukemia: Results of a Phase I Trial.

Yannis K Valtis, David Nemirovsky, Andriy Derkach

Pageof 2

Frequent Collaborators

5 joint publications

Sridevi Rajeeve

5 joint publications

Sergio Giralt

5 joint publications

Carlyn Rose Tan

5 joint publications

Gunjan Shah